Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study

Table 1 Patient characteristics

Age	30 (14 to 56)
Sex (M:F)	5:28
SLE duration (months)	10 (0 to 312)
Nephritis duration (months)	2 (0 to 56)
Active nephritis until treatment onset (months)^‡	1 (0 to 15)
Renal biopsy
WHO class III	20 (61)
IV	7 (21)
V with III/IV lesions	6 (18)
Activity index	4 (2 to 18)
Chronicity index	1 (0 to 6)
Crescents (cellular and/or fibrous)	10 (30)
Fibrinoid necrosis/Karyorrhexis	9 (27)
Interstitial fibrosis	17 (51)
Glomerulosclerosis	18 (54)
Tubular atrophy	22 (67)
Positive Anti-dsDNA antibodies	32 (97)
Positive Anti-Ro antibodies	16 (48)
Positive Anti-La antibodies	6 (18)
Positive Anti-Sm antibodies	4 (12)
Positive anti-U1RNP antibodies	8 (24)
Positive antiphospholipid antibodies	9/26 (35)
Low C3 at baseline (<70 mg/dl)	9/26 (35)
Low C4 at baseline (<10 mg/dl)	19/26 (73)

^‡ Proteinuria > 500 mg/24 h, and/or hematuria (> 5 hpf), and/or pyuria (> 5 hpf), and/or casts (> 1 hpf), and/or ≥ 30% decrease in GFR in at least two measurements. Values are expressed as either proportions or median (range).
M, male; F, female; SLE, systemic lupus erythematosus; WHO, World Health Organization; hpf, high power field; GFR, glomerular filtration rate.

ISSN: 1478-6362